Literature DB >> 2462795

Genetic variation among geographic isolates of Rift Valley fever virus.

J K Battles1, J M Dalrymple.   

Abstract

The genetic variation of Rift Valley fever virus (RVFV) was estimated by sequencing a portion of the M segment RNA of 22 isolates from a variety of host species collected over 34 years in 6 African countries. The M segment RNA of the Egyptian isolate, ZH501, which has been molecularly cloned and sequenced, was used as a reference for these comparisons. Specific gene regions, responsible for antigenic determinants presumed to play a role in protection against disease, were emphasized in these investigations. Comparative sequence data revealed that most isolates were very similar to ZH501 at both the nucleic acid and deduced amino acid sequence levels. Nucleic acid sequence variation range was 0-4.5%. Amino acid sequence variation range was 0-2.4%. We identified specific amino acid coding changes which may be involved in virus neutralization and may contribute to the virulence characteristics of RVFV.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462795     DOI: 10.4269/ajtmh.1988.39.617

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

1.  Infectious enveloped RNA virus antigenic chimeras.

Authors:  S D London; A L Schmaljohn; J M Dalrymple; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 2.  Emerging infectious diseases: the Bunyaviridae.

Authors:  Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

3.  Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

4.  Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine.

Authors:  Reuben K Soi; Fred R Rurangirwa; Travis C McGuire; Paul M Rwambo; James C DeMartini; Timothy B Crawford
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

5.  Characterization of the Candiru antigenic complex (Bunyaviridae: Phlebovirus), a highly diverse and reassorting group of viruses affecting humans in tropical America.

Authors:  Gustavo Palacios; Robert Tesh; Amelia Travassos da Rosa; Nazir Savji; Wilson Sze; Komal Jain; Robert Serge; Hilda Guzman; Carolina Guevara; Marcio R T Nunes; Joaquim P Nunes-Neto; Tadeusz Kochel; Stephen Hutchison; Pedro F C Vasconcelos; W Ian Lipkin
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin.

Authors:  Sheli R Radoshitzky; Lian Dong; Xiaoli Chi; Jeremiah C Clester; Cary Retterer; Kevin Spurgers; Jens H Kuhn; Sarah Sandwick; Gordon Ruthel; Krishna Kota; Dutch Boltz; Travis Warren; Philip J Kranzusch; Sean P J Whelan; Sina Bavari
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

7.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

8.  Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Authors:  Nandadeva Lokugamage; Alexander N Freiberg; John C Morrill; Tetsuro Ikegami
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells.

Authors:  J Dubuisson; C M Rice
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.